Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.

Niedersüss-Beke D, Puntus T, Kunit T, Grünberger B, Lamche M, Loidl W, Böhm R, Kraischits N, Kudlacek S, Schramek P, Meran JG.

Oncology. 2017 Apr 12. doi: 10.1159/000463389. [Epub ahead of print]

PMID:
28399521
2.

Virus-Enabled Biosensor for Human Serum Albumin.

Ogata AF, Edgar JM, Majumdar S, Briggs JS, Patterson SV, Tan MX, Kudlacek ST, Schneider CA, Weiss GA, Penner RM.

Anal Chem. 2017 Jan 17;89(2):1373-1381. doi: 10.1021/acs.analchem.6b04840. Epub 2017 Jan 3.

PMID:
27989106
3.

Shear-stress-mediated refolding of proteins from aggregates and inclusion bodies.

Yuan TZ, Ormonde CF, Kudlacek ST, Kunche S, Smith JN, Brown WA, Pugliese KM, Olsen TJ, Iftikhar M, Raston CL, Weiss GA.

Chembiochem. 2015 Feb 9;16(3):393-6. doi: 10.1002/cbic.201402427. Epub 2015 Jan 23.

4.

Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status.

Dovjak P, Dorfer S, Föger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P.

Gerontology. 2014;60(6):493-501. doi: 10.1159/000358303. Epub 2014 Jun 12.

PMID:
24943689
5.

Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture.

Rauner M, Föger-Samwald U, Kurz MF, Brünner-Kubath C, Schamall D, Kapfenberger A, Varga P, Kudlacek S, Wutzl A, Höger H, Zysset PK, Shi GP, Hofbauer LC, Sipos W, Pietschmann P.

Bone. 2014 Jul;64:281-7. doi: 10.1016/j.bone.2014.04.022. Epub 2014 Apr 26.

PMID:
24780878
6.

Low bone mineral density and fragility fractures in permanent vegetative state patients.

Oppl B, Michitsch G, Misof B, Kudlacek S, Donis J, Klaushofer K, Zwerina J, Zwettler E.

J Bone Miner Res. 2014;29(5):1096-100. doi: 10.1002/jbmr.2122.

7.

Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.

Bieglmayer C, Dimai HP, Gasser RW, Kudlacek S, Obermayer-Pietsch B, Woloszczuk W, Zwettler E, Griesmacher A.

Wien Med Wochenschr. 2012 Nov;162(21-22):464-77. doi: 10.1007/s10354-012-0133-9. Epub 2012 Aug 14.

PMID:
22890523
8.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
9.

Measuring quality of life with the German Osteoporosis Quality of Life Questionnaire in women with osteoporosis.

Kerschan-Schindl K, Patsch J, Kudlacek S, Gleiss A, Pietschmann P.

Wien Klin Wochenschr. 2012 Aug;124(15-16):532-7. Epub 2012 Jul 25.

PMID:
22829299
10.

Update on denosumab in postmenopausal osteoporosis--recent clinical data.

Muschitz C, Fahrleitner-Pammer A, Huber J, Preisinger E, Kudlacek S, Resch H.

Wien Med Wochenschr. 2012 Sep;162(17-18):374-9. doi: 10.1007/s10354-012-0116-x. Epub 2012 Jun 12. Review. Erratum in: Wien Med Wochenschr. 2013 Feb;163(3-4):106.

PMID:
22688622
11.

[Case report of a patient with renal cell cancer and his fateful progress - Breaking Bad News].

Kudlacek S, Meran JG.

Wien Med Wochenschr. 2012 Jan;162(1-2):3-7. doi: 10.1007/s10354-011-0042-3. German.

PMID:
22328047
12.

Influence of age and gender on associations of body mass index with bone mineral density, bone turnover markers and circulating calcium-regulating and bone-active sex hormones.

Puntus T, Schneider B, Meran J, Peterlik M, Kudlacek S.

Bone. 2011 Oct;49(4):824-9. doi: 10.1016/j.bone.2011.06.003. Epub 2011 Jun 12.

PMID:
21700003
13.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.

N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.

14.

The bone marker plot: an innovative method to assess bone turnover in women.

Bieglmayer C, Kudlacek S.

Eur J Clin Invest. 2009 Mar;39(3):230-8. doi: 10.1111/j.1365-2362.2009.02087.x.

PMID:
19260953
15.

High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy.

Mikosch P, Kerschan-Schindl K, Woloszczuk W, Stettner H, Kudlacek S, Kresnik E, Gallowitsch HJ, Lind P, Pietschmann P.

Thyroid. 2008 Jan;18(1):27-33. doi: 10.1089/thy.2007.0186.

PMID:
18302515
16.

Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men.

Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P.

Exp Clin Endocrinol Diabetes. 2008 Aug;116(8):491-5. Epub 2007 Dec 10.

PMID:
18072013
17.

[Clinical relevance of biomarkers in cancer related bone disease].

Beke D, Kudlacek S, Meran JG.

Wien Med Wochenschr. 2007;157(15-16):375-80. Review. German.

PMID:
17922085
18.

[Systemic oncological treatment of bladder cancer].

Meran JG, Kudlacek S, Beke D.

Wien Med Wochenschr. 2007;157(7-8):157-61. Review. German.

PMID:
17492412
19.

[The hormone refractory prostate cancer - a challenge for the internal specialist].

Kudlacek S, Meran JG, Beke D.

Wien Med Wochenschr. 2007;157(7-8):145-8. Review. German.

PMID:
17492409
20.

Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men.

Gugatschka M, Hoeller A, Fahrleitner-Pammer A, Dobnig H, Pietschmann P, Kudlacek S, Obermayer-Pietsch B.

J Endocrinol Invest. 2007 Jan;30(1):46-51.

PMID:
17318022

Supplemental Content

Loading ...
Support Center